The 2014 annual meeting of stockholders of Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) was held on May 28, 2014. At the 2014 annual meeting of stockholders, the Company’s stockholders voted on the election of three directors, each for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014 and the approval, on an advisory basis, of the compensation of the Company’s named executive officers. Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) stock opened today at $1.15 and is currently trading at $1.09. The stock showed a positive weekly performance of 35.63%.
Atossa Genetics Inc. (NASDAQ:ATOS) said that it has hired John E. Sawyer as Senior Vice President of Global Regulatory Affairs and Quality Assurance, effective June 1. Atossa Genetics Inc. (NASDAQ:ATOS) stock opened at $1.58, in current trading session and currently is at $1.60, by gaining 1.26%. The 52 week range of $1.15 – $7.75. Company’s market capitalization is 39.08 million.
MEI Pharma, Inc. (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza® (azacitidine) in elderly patients with newly diagnosed acute myeloid leukemia (AML) who are unsuitable for intensive chemotherapy. MEI Pharma Inc. (NASDAQ:MEIP) stock is currently trading at $7.09. The EPS of the stock is -1.14. Company’s market capitalization is 153.20 million.
Celgene Corporation (NASDAQ:CELG) subsidiary, Celgene International, announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4). Celgene Corporation (NASDAQ:CELG) stock opened the session at $161.41, and now is at $161.05. The 52 week range of the Celgene Corporation (NASDAQ:CELG) stock remained $110.53 – $174.66 and the day range was $160.90 – $162.15.
RXi Pharmaceuticals Corp. (NASDAQ:RXII) has developed a unique platform, known as sd-rxRNA that bridges the gap between antisense and RNAi. The technology has a single-stranded phosphorothioate region, a short duplex region, and contains a variety of nuclease-stabilizing and lipophilic chemical modifiers. These features provide both efficiency cellular uptake and long-lasting intracellular activity. RXi Pharmaceuticals Corp (NASDAQ:RXII) stock opened today at $3.10 and is currently trading at $3.14. The stock showed a positive weekly performance of 5.46%.